The Generative Biology Revolution: Accelerating Drug Discovery with Protein Design

The ability to design proteins to perform desired functions will transform drug development. In particular, with AI and machine learning, scientists gain the ability to engineer antibody-based drugs, including multispecifics which engage multiple targets. By altering existing protein structures or developing proteins de novo, biologics will become more effective and specific.

In this episode, we talk to Suzanne Edavettal, the executive director of Protein Engineering at Amgen. We discuss how protein design affects drug development and success rates in the clinic today and in the future.

To dive further into this topic, please join Amgen scientists at the Generative Biology Q&A webinar discussion on July 20^th, 2022. Register for the event here.

 

The Generative Biology Revolution is a special edition podcast series produced by The Scientist’s Creative Services Team.

This series is brought to you by Amgen, a pioneer in the science of using living cells to make biologic medicines. They helped invent the processes and tools that built the global biotech industry, and have since reached millions of patients suffering from serious illnesses around the world with their medicines.

Generative biology is a revolutionary approach to drug discovery and development that leverages machine learning and AI to design novel protein therapeutics. It holds the potential to enhance the speed and efficiency of discovery. In this series, Ray Deshaies, senior vice president of Global Research at Amgen, discusses how generative biology is transforming drug discovery to make it more predictable, shorten timelines, and increase success rates of bringing life-saving medicines to patients who need them most.